Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Srihari Uppalapati"'
Publikováno v:
Japanese Journal of Clinical Oncology. 45:749-754
Objective: Altered differentiation is a common feature of haematopoietic malignancies with poor prognosis. CAAT/enhancer binding protein alpha (C/EBPα) is a key transcription factor that regulates myeloid differentiation. This study is aimed to know
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b94100da9d708d375894420cb440cf56
https://doi.org/10.1093/jjco/hyv064
https://doi.org/10.1093/jjco/hyv064
Autor:
Srihari Uppalapati, Sangeeta Jiwtani, Raghunadharao Digumarti, Sailaja Kagita, Vijay Gandhi Linga, S. Gundeti
Publikováno v:
Tumor Biology. 35:4443-4446
Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management. Most of the CML patients achieve major responses, but a proportion (nearly 25-35%) of them develop drug resistance. Molecular monitoring using quantitative real-time PCR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e7203550ee77e43bf25114e114586fa
https://doi.org/10.1007/s13277-013-1585-2
https://doi.org/10.1007/s13277-013-1585-2
Autor:
Ramesh Mullangi, Kasiram Katneni, Srihari Uppalapati, Sangeeta Jiwatani, Vijay V. Upreti, Raghunadharao Digumarti, Rao N. V. S. Mamidi, Anjna Surath, Nuggehally R. Srinivas, Maddali Lakshmi Srinivas, Arani Chatterjee
Publikováno v:
The Journal of Clinical Pharmacology. 45:453-460
The purpose of this bridging phase I study was to characterize the toxicity, pharmacokinetics, and antitumor effects of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory solid tumor patients. DRF-1042 was given daily for 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c46b100e89d6fd6a502c4a88fbf270
https://doi.org/10.1177/0091270004270225
https://doi.org/10.1177/0091270004270225
Autor:
Arani Chatterjee, Swaminathan Subramaniam, Sangeeta Jiwatani, Vijay V. Upreti, Anjna Surath, Srihari Uppalapati, Nuggehally R. Srinivas, Raghunadharao Digumarti, Kasiram Katneni, Rao N. V. S. Mamidi, Maddali Lakshmi Srinivas
Publikováno v:
The Journal of Clinical Pharmacology. 44:723-736
The objective of this study was to characterize the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and antitumor effects of DRF-1042, a novel camptothecin analog, in refractory solid tumor patients. DRF-1042 was given
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d835fcfc557cb124216427293c2f47f
https://doi.org/10.1177/0091270004265647
https://doi.org/10.1177/0091270004265647
Autor:
Narayana Nagesh, Vijay Gandhi Linga, Sangeeta Jiwatani, S. Gundeti, Srihari Uppalapati, Sailaja Kagita, Raghunadharao Digumarti
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 35(7)
Mutations in the Bcr-Abl kinase domain (KD) are a major cause for acquired resistance to imatinib (IM) treatment and have been associated with progression and poor prognosis in chronic myeloid leukemia patients. The present study includes 63 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf794736b9394812d242956c8100d07
https://pubmed.ncbi.nlm.nih.gov/24763825
https://pubmed.ncbi.nlm.nih.gov/24763825
Autor:
A Abhyankar, Senthil Rajappa, Srihari Uppalapati, Sangeeta Jiwatani, Raghunadharao Digumarti, C Pal, S. Gundeti
Publikováno v:
Indian journal of cancer. 45(4)
Background: There is general belief that patients who enrolled on a clinical trial have better outcomes compared to those who are treated outside of a trial. We analyzed if there was a 'trial effect' for patients with advanced non-small cell lung can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b073d6bb2fb9dc2d5badf56a16bb3541
https://pubmed.ncbi.nlm.nih.gov/19112204
https://pubmed.ncbi.nlm.nih.gov/19112204
Autor:
Praveen Chowdary Myneni, Srihari Uppalapati, Sangeeta Jiwatani, Raghunadharao Digumarti, Venkata Ramana Gogula
Publikováno v:
Journal of Clinical Oncology. 31:7080-7080
7080 Background: NRC-AN-019 is an orally administered tyrosine kinase inhibitor (TKI) of the Bcr-Abl protein-tyrosine kinase. The drug was given to patients as a ready-to-use liquid formulation. Methods: The primary objectives of the Phase-I study we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2732706a20c18013dacefb29fba2e74a
https://doi.org/10.1200/jco.2013.31.15_suppl.7080
https://doi.org/10.1200/jco.2013.31.15_suppl.7080
Publikováno v:
Journal of Clinical Oncology. 24:4086-4086
4086 Background: Gastric cancer is the second most common gastrointestinal cancer in our hospital based cancer registry. This retrospective analysis aims at studying the epidemiology and treatment patterns for gastric cancer at our hospital, which is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::109957a097fc81a7ce0681f461b03e02
https://doi.org/10.1200/jco.2006.24.18_suppl.4086
https://doi.org/10.1200/jco.2006.24.18_suppl.4086